RAMOT at Tel Aviv University Ltd.

Compositions for treating ophthalmic medical conditions

Posted by RAMOT at Tel Aviv University Ltd.Responsive · Knowhow and Research output · Israel

Send your request

Summary of the technology

Compositions for treating ophthalmic medical conditions
Project ID : 10-2013-556

Description of the technology

Additional information can be provided upon request.

Project manager

Rona Samler
VP, BD Physical Science, Medical Device, Chemistry

Project researchers

Michael Belkin
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Goldshlager Eye Center-Sheba

Aviv Shaish
Sheba Medical Center,

Dror Harats
Sheba Medical Center,

Ygal Rotenstreich
Sheba Medical Center,

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Micro- and Nanotechnology related to Biological sciences
  • Therapeutic
  • Clinical Medicine
  • Pharmaceutical Indications
  • ophthalmology

About RAMOT at Tel Aviv University Ltd.

Technology Transfer Office from Israel

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at

Similar Technology Offers

Guided Regeneration Gel: A novel biocompatible hydrogel for peripheral nerve reconstruction and wound healing

Guided Regeneration Gel (GRG) is a novel biocompatible, biodegradable hydrogel for peripheral nerve reconstruction and wound healing. GRG, similar to the extracellular matrix (ECM), is transparent, highly viscous, malleable and adaptable to various shapes and formats. GRG is based on mixed-intercalated (for short time lasting effects) or cross-linked hyaluronic acid together with SOD and novel laminin bioactive peptides (for long lasting effects), serving together as guiding tracks for cell migration and regeneration. GRG can be used for ex-vivo or in-vivo tissue formation and for treatment of damaged or lost tissue. Project ID : 2-2011-6

  • +6 months
  • Hide post

Oncomir expression directed targeted chemotherapy

MicroRNAs (miRNAs) are an abundant class of short endogenous noncoding RNAs that act as post-transcriptional regulators of gene expression by base-pairing with their target mRNAs. To date, several hundred miRNAs have been described in humans and a large number of them have been implicated in the development and progression of cancer. miRNAs that have been experimentally shown to directly induce tumor phenotypes (i.e., formation) have been termed "oncomirs". In this invention we utilize this differential expression of a known oncomir to selectively target cancer cells. Selected targeting is achieved by differentially expressing a "killer gene" in the cancerous cells, by expressing it under the control of the oncomir promoter. Such “killer gene” could be a toxin (such as the diphtheria toxin-A), the viral tymidine kinase gene, or an apoptosis inducing genes, all of these genes were previously shown to be efficient in destruction of cancer cells. The specific oncomir was shown to target multiple tumor/metastasis suppressor genes and to have a role in tumor growth, invasion and metastasis. Numerous studies show that this oncomir is exclusively expressed in cancerous cell lines and solid human tumors, but not in non-transformed cell lines or in the adjacent non cancerous tissue. Project ID : 2-2010-8

  • +6 months
  • Hide post

Immunotherapy for the prevention and treatment of osseous metastasis

Immunotherapy for the prevention and treatment of osseous metastasis Project ID : 10-2007-91

  • +6 months
  • Hide post

Improved Calcitonin-based Therapeutics

The aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. Project ID : 10-2007-103

  • +6 months
  • Hide post

Novel markers for the identification and isolation of stem and progenitor cells

A series of novel markers: (1) chromatin remodeling protein factor termed (CHD9/CReMM), (2) A cell adhesion protein termed (SVEP1), (3) A kinesin protein termed (MS-KIF18A), (4) RNA processing factor (SRRF/hNRNP-L) have been developed as novel markers for the identification and isolation of stem and progenitor cells. Project ID : 10-2007-104

  • +6 months
  • Hide post

View other related tech offers

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Other users also viewed

Cell Therapy for Diabetes: Expansion and re-differentiation of adult human pancreatic islet cells for transplantationGSK-3 Peptide Inhibitors for the Treatment of CNS Related DisordersNovel oral formulation of InsulinNovel ALS biomarkers:Towards diagnostics and potential therapyDrug Treatments Targeting Glioma Microenvironment: CD38 inhibitor as a Potential Therapeutic Approach for Glioma Treatment